Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.57 |
| ▸ | BDNF | P23560 | 3/20 | 0.46 |
| ▸ | PTN | P21246 | 2/20 | 0.46 |
| ▸ | MDK | P21741 | 2/20 | 0.46 |
| ▸ | SERPINC1 | P01008 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 10/20 | 0.39 |
| ▸ | PF4 | P02776 | 2/20 | 0.39 |
| ▸ | FGF1 | P05230 | 1/20 | 0.35 |
| ▸ | FGF2 | P09038 | 1/20 | 0.35 |
| ▸ | IFNG | P01579 | 1/20 | 0.35 |
| ▸ | BMP2 | P12643 | 1/20 | 0.35 |
| ▸ | CCL2 | P13500 | 1/20 | 0.35 |
| ▸ | VEGFA | P15692 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
| ▸ | BMP6 | P22004 | 1/20 | 0.35 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.35 |
| ▸ | CCL11 | P51671 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
| ▸ | SELPLG | Q14242 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13311345 | 0.91 | F10 (0.64) | F10BDNFPTNMDKSERPINC1 | |
| SCHEMBL4593793 | 0.91 | F10 (0.64) | F10BDNFPTNMDKSERPINC1 | |
| SCHEMBL14670002 | 0.91 | F10 (0.64) | F10BDNFPTNMDKSERPINC1 | |
| SCHEMBL15416845 | 0.86 | F10 (0.57) | F10BDNFPTNMDKSERPINC1 | |
| SCHEMBL23337007 | 0.81 | F10 (0.64) | F10BDNFPTNMDKSERPINC1 | |
| SCHEMBL29308178 | 0.80 | F10 (0.79) | F10BDNFPTNMDKSERPINC1 | |
| SCHEMBL12514534 | 0.80 | F10 (0.60) | F10BDNFPTNMDKSERPINC1 | |
| SCHEMBL16509456 | 0.80 | F10 (0.77) | F10BDNFPTNMDKSERPINC1 | |
| SCHEMBL23135895 | 0.79 | F10 (0.62) | F10BDNFPTNMDKSERPINC1 | |
| SCHEMBL29647566 | 0.78 | F10 (0.60) | F10BDNFPTNMDKSERPINC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3232193-B1 | DIAGNOSIS OF MPS I DISORDERS BY MEASURING NON-REDUCING ENDS OF GAGS AFTER ENZYMATIC DIGEST | BIOMARIN PHARM INC (US) | 2023-03-01 | — | — | EP | claimed |
| US-20220404379-A1 | SEQUENCING METHOD, SYSTEM AND KIT OF LOW MOLECULAR WEIGHT HEPARIN OLIGOSACCHARIDES | SHANDONG UNIVERSITY (CN) | 2022-12-22 | — | — | US | claimed |
| US-20220404375-A1 | ANTIBODIES TO DISULFATED HEPARIN DISACCHARIDE IN THE DIAGNOSIS OF NEUROPATHY | WASHINGTON UNIVERSITY | 2022-12-22 | — | — | US | claimed |
| CN-113393904-B | Method and system for detecting low-molecular heparin sugar chain sequence and sequencing kit | 山东大学 | 2022-10-18 | — | — | CN | claimed |
| US-20250281523-A1 | SULFATED GLYCOSAMINOGLYCAN COMPOUNDS, METHODS, AND USES THEREOF | CALIFORNIA INST OF TECHN (US) | 2025-09-11 | — | — | US | disclosed |
| CN-118308338-A | PL35 family chondroitin sulfate lyase and encoding gene and application thereof | 山东第二医科大学 | 2024-07-09 | — | — | CN | disclosed |
| US-11903963-B2 | Short-acting heparin-based anticoagulant compounds and methods | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-02-20 | — | — | US | disclosed |
| EP-3232193-B1 | DIAGNOSIS OF MPS I DISORDERS BY MEASURING NON-REDUCING ENDS OF GAGS AFTER ENZYMATIC DIGEST | BIOMARIN PHARM INC (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220404379-A1 | SEQUENCING METHOD, SYSTEM AND KIT OF LOW MOLECULAR WEIGHT HEPARIN OLIGOSACCHARIDES | SHANDONG UNIVERSITY (CN) | 2022-12-22 | — | — | US | disclosed |
| US-20220404375-A1 | ANTIBODIES TO DISULFATED HEPARIN DISACCHARIDE IN THE DIAGNOSIS OF NEUROPATHY | WASHINGTON UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| CN-113393904-B | Method and system for detecting low-molecular heparin sugar chain sequence and sequencing kit | 山东大学 | 2022-10-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281523-A1 | SULFATED GLYCOSAMINOGLYCAN COMPOUNDS, METHODS, AND USES THEREOF | HPSE, CSGALNACT1, DDOST | F10 2036/4885BDNF 375/4885PTN 398/4885 |
| US-11903963-B2 | Short-acting heparin-based anticoagulant compounds and methods | HPSE, STS, SULT1A1 | F10 425/4885BDNF 4395/4885PTN 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.